Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA

doi:10.1007/s00259-017-3728-y

. 2017 Aug;44(9):1588-1601.

doi: 10.1007/s00259-017-3728-y. Epub 2017 May 25.

Guideline for PET/CT imaging of neuroendocrine neoplasms with ⁶⁸Ga-DOTA-conjugated somatostatin receptor targeting peptides and ¹⁸F-DOPA

Murat Fani Bozkurt¹, Irene Virgolini², Sona Balogova^{3

4}, Mohsen Beheshti^{5

6}, Domenico Rubello⁷, Clemens Decristoforo², Valentina Ambrosini⁸, Andreas Kjaer⁹, Roberto Delgado-Bolton¹⁰, Jolanta Kunikowska¹¹, Wim J G Oyen¹², Arturo Chiti¹³, Francesco Giammarile¹⁴, Anders Sundin, Stefano Fanti⁸

Affiliations

¹ Hacettepe University Faculty of Medicine Department of Nuclear Medicine, Ankara, Turkey. fanibozkurt@yahoo.com.
² Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria.
³ Department of Nuclear Medicine, Comenius University and St. Elisabeth Oncology Institute, Bratislava, Slovakia.
⁴ Department of Nuclear Medicine, Tenon Hospital AP-HP & Université Pierre et Marie Curie, Paris, France.
⁵ PET-CT Center, Department of Nuclear Medicine & Endocrinology, St. Vincent's Hospital, Linz, Austria.
⁶ Department of Nuclear Medicine, Paracelsus Medical University, Salzburg, Austria.
⁷ Department of Nuclear Medicine, PET Center and Medical Physics and Radiology, Santa Maria della Misericordia Hospital, Rovigo, Italy.
⁸ Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Bologna, Italy.
⁹ Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark.
¹⁰ Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, San Pedro Hospital and Centre for Biomedical Research of La Rioja (CIBIR), Logroño, Spain. rbiolton@gmail.com.
¹¹ Nuclear Medicine, Medical University of Warsaw, Warsaw, Poland.
¹² Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
¹³ Nuclear Medicine Department, Humanitas University, Rozzano, MI, Italy.
¹⁴ Nuclear Medicine, University of Lyon, Lyon, France.

PMID: 28547177
DOI: 10.1007/s00259-017-3728-y

Guideline for PET/CT imaging of neuroendocrine neoplasms with ⁶⁸Ga-DOTA-conjugated somatostatin receptor targeting peptides and ¹⁸F-DOPA

Murat Fani Bozkurt et al. Eur J Nucl Med Mol Imaging. 2017 Aug.

. 2017 Aug;44(9):1588-1601.

doi: 10.1007/s00259-017-3728-y. Epub 2017 May 25.

Authors

Affiliations

¹ Hacettepe University Faculty of Medicine Department of Nuclear Medicine, Ankara, Turkey. fanibozkurt@yahoo.com.
² Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria.
³ Department of Nuclear Medicine, Comenius University and St. Elisabeth Oncology Institute, Bratislava, Slovakia.
⁴ Department of Nuclear Medicine, Tenon Hospital AP-HP & Université Pierre et Marie Curie, Paris, France.
⁵ PET-CT Center, Department of Nuclear Medicine & Endocrinology, St. Vincent's Hospital, Linz, Austria.
⁶ Department of Nuclear Medicine, Paracelsus Medical University, Salzburg, Austria.
⁷ Department of Nuclear Medicine, PET Center and Medical Physics and Radiology, Santa Maria della Misericordia Hospital, Rovigo, Italy.
⁸ Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Bologna, Italy.
⁹ Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark.
¹⁰ Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, San Pedro Hospital and Centre for Biomedical Research of La Rioja (CIBIR), Logroño, Spain. rbiolton@gmail.com.
¹¹ Nuclear Medicine, Medical University of Warsaw, Warsaw, Poland.
¹² Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
¹³ Nuclear Medicine Department, Humanitas University, Rozzano, MI, Italy.
¹⁴ Nuclear Medicine, University of Lyon, Lyon, France.

PMID: 28547177
DOI: 10.1007/s00259-017-3728-y

Erratum in

Erratum to: Guideline for PET/CT imaging of neuroendocrine neoplasms with ⁶⁸Ga-DOTA-conjugated somatostatin receptor targeting peptides and ¹⁸F-DOPA.
Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, Ambrosini V, Kjaer A, Delgado-Bolton R, Kunikowska J, Oyen WJG, Chiti A, Giammarile F, Sundin A, Fanti S. Bozkurt MF, et al. Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2150-2151. doi: 10.1007/s00259-017-3807-0. Eur J Nucl Med Mol Imaging. 2017. PMID: 28856372 No abstract available.

Abstract

Purpose & methods: Neuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using ⁶⁸Ga-DOTA-conjugated peptides, as well as ¹⁸F-DOPA imaging for various neuroendocrine neoplasms.

Results & conclusion: The previous procedural guideline by EANM regarding the use PET/CT tumour imaging with ⁶⁸Ga-conjugated peptides has been revised and updated with the relevant and recent literature in the field with contribution of distinguished experts.

Keywords: 18F–DOPA; 18F–FDG; 68Ga-DOTANOC; 68Ga-DOTATATE; 68Ga-DOTATOC; Foregut-NET; Hindgut-NET; Hyperinsulism in infants; Midgut-NET; Neuroendocrine neoplasms; Neuroendocrine tumours; Paraganglioma; Pet/Ct; Pheochromoacytoma; Thyroid medullary cancer.

PubMed Disclaimer

Cited by

Impact of segmentation and discretization on radiomic features in ⁶⁸Ga-DOTA-TOC PET/CT images of neuroendocrine tumor.
Liberini V, De Santi B, Rampado O, Gallio E, Dionisi B, Ceci F, Polverari G, Thuillier P, Molinari F, Deandreis D. Liberini V, et al. EJNMMI Phys. 2021 Feb 27;8(1):21. doi: 10.1186/s40658-021-00367-6. EJNMMI Phys. 2021. PMID: 33638729 Free PMC article.
Bone metastases in midgut neuroendocrine tumors: imaging characteristics, distribution, and risk factors.
Lelièvre M, Triumbari EKA, Brixi H, Perrier M, Cadiot G, Deguelte S, Morland D. Lelièvre M, et al. Endocrine. 2022 Nov;78(2):380-386. doi: 10.1007/s12020-022-03160-2. Epub 2022 Oct 7. Endocrine. 2022. PMID: 36203032
The Role of ¹⁸F-FDOPA PET/CT in Recurrent Medullary Thyroid Cancer Patients with Elevated Serum Calcitonin Levels.
Araz M, Soydal Ç, Demir Ö, Gökcan MK, Küçük NÖ. Araz M, et al. Mol Imaging Radionucl Ther. 2023 Feb 23;32(1):1-7. doi: 10.4274/mirt.galenos.2022.81904. Mol Imaging Radionucl Ther. 2023. PMID: 36815513 Free PMC article.
Biodistribution and first clinical results of ¹⁸F-SiFAlin-TATE PET: a novel ¹⁸F-labeled somatostatin analog for imaging of neuroendocrine tumors.
Ilhan H, Lindner S, Todica A, Cyran CC, Tiling R, Auernhammer CJ, Spitzweg C, Boeck S, Unterrainer M, Gildehaus FJ, Böning G, Jurkschat K, Wängler C, Wängler B, Schirrmacher R, Bartenstein P. Ilhan H, et al. Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):870-880. doi: 10.1007/s00259-019-04501-6. Epub 2019 Sep 6. Eur J Nucl Med Mol Imaging. 2020. PMID: 31492994
Diagnostic Management of Gastroenteropancreatic Neuroendocrine Neoplasms: Technique Optimization and Tips and Tricks for Radiologists.
Pellegrino F, Granata V, Fusco R, Grassi F, Tafuto S, Perrucci L, Tralli G, Scaglione M. Pellegrino F, et al. Tomography. 2023 Jan 27;9(1):217-246. doi: 10.3390/tomography9010018. Tomography. 2023. PMID: 36828370 Free PMC article. Review.

See all "Cited by" articles

References

1. Clin Nucl Med. 2015 Aug;40(8):682-4 - PubMed
1. Eur J Nucl Med. 1998 Oct;25(10 ):1396-403 - PubMed
1. Clin Cancer Res. 2010 Feb 1;16(3):978-85 - PubMed
1. J Nucl Med. 2009 Aug;50(8):1214-21 - PubMed
1. J Nucl Med. 2013 Mar;54(3):364-72 - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations

[1] Clin Nucl Med. 2015 Aug;40(8):682-4 - PubMed

[2] Clin Nucl Med. 2015 Aug;40(8):682-4 - PubMed

[3] Eur J Nucl Med. 1998 Oct;25(10 ):1396-403 - PubMed

[4] Eur J Nucl Med. 1998 Oct;25(10 ):1396-403 - PubMed

[5] Clin Cancer Res. 2010 Feb 1;16(3):978-85 - PubMed

[6] Clin Cancer Res. 2010 Feb 1;16(3):978-85 - PubMed

[7] J Nucl Med. 2009 Aug;50(8):1214-21 - PubMed

[8] J Nucl Med. 2009 Aug;50(8):1214-21 - PubMed

[9] J Nucl Med. 2013 Mar;54(3):364-72 - PubMed

[10] J Nucl Med. 2013 Mar;54(3):364-72 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Guideline for PET/CT imaging of neuroendocrine neoplasms with ⁶⁸Ga-DOTA-conjugated somatostatin receptor targeting peptides and ¹⁸F-DOPA

Affiliations

Guideline for PET/CT imaging of neuroendocrine neoplasms with ⁶⁸Ga-DOTA-conjugated somatostatin receptor targeting peptides and ¹⁸F-DOPA

Authors

Affiliations

Erratum in

Abstract

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Erratum in

Abstract

Similar articles

Cited by

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources